A meta-analysis of 8 randomized trials (1792 patients, 2947 patient-years of follow-up) showed that acyclovir ( §3200 mg/day) offered a significant survival benefit (P Å .006 by log-rank test) in human immunodeficiency virus (HIV) infection. The treatment effect did not vary significantly in patient subgroups of different CD4 cell counts, hemoglobin levels, age, race, and sex, and with or without AIDS diagnosis. Acyclovir treatment (hazard ratio, 0.78; 95% confidence interval [CI], 0.65 -0.93), higher CD4 cell count (P õ .001), higher hemoglobin level (P õ .001), and younger age (P õ .001) reduced the hazard of mortality. Acyclovir decreased herpes simplex virus infections (odds ratio [OR], 0.28; 95% CI, 0.21 -0.37) and varicella-zoster virus infections (OR, 0.29; 95% CI, 0.13 -0.63) but not cytomegalovirus disease or mortality from lymphoma or Kaposi's sarcoma. A survival advantage was seen specifically in studies with high incidence of clinical herpesvirus infections ( §25% per year). Given the wide confidence intervals, the small effect in low-risk patients, and recent changes in HIV therapeutics, the results should be interpreted cautiously, but the metaanalysis supports the importance of pathogenetic interactions between herpesviruses and HIV.
A meta-analysis of 8 randomized trials (1792 patients, 2947 patient-years of follow-up) showed that acyclovir ( §3200 mg/day) offered a significant survival benefit (P Å .006 by log-rank test) in human immunodeficiency virus (HIV) infection. The treatment effect did not vary significantly in patient subgroups of different CD4 cell counts, hemoglobin levels, age, race, and sex, and with or without AIDS diagnosis. Acyclovir treatment (hazard ratio, 0.78; 95% confidence interval [CI], 0.65 -0.93), higher CD4 cell count (P õ .001), higher hemoglobin level (P õ .001), and younger age (P õ .001) reduced the hazard of mortality. Acyclovir decreased herpes simplex virus infections (odds ratio [OR], 0.28; 95% CI, 0.21 -0.37) and varicella-zoster virus infections (OR, 0.29; 95% CI, 0.13 -0.63) but not cytomegalovirus disease or mortality from lymphoma or Kaposi's sarcoma. A survival advantage was seen specifically in studies with high incidence of clinical herpesvirus infections ( §25% per year). Given the wide confidence intervals, the small effect in low-risk patients, and recent changes in HIV therapeutics, the results should be interpreted cautiously, but the metaanalysis supports the importance of pathogenetic interactions between herpesviruses and HIV.
The high incidence of morbidity related to herpesviruses in with antiherpetic activity tested for its clinical efficacy in HIVinfected patients. Despite 10 years of clinical research, a final human immunodeficiency virus (HIV) -infected patients, and the recognition that these agents may be important copathogens consensus on its efficacy or lack thereof has not been reached. Nonrandomized cohort studies reached conflicting conclusions, [1 -3] , may induce HIV replication [1, 2] , and may potentially accelerate the destruction of the immune system, has long ranging from large and clinically meaningful efficacy [4] to potential harm [5] . Nonrandomized studies may be prone to prompted interest in the assessment of antiherpetic interventions in HIV infection. Acyclovir was one of the first agents bias that is impossible to adjust for and interpret. However, a large body of randomized evidence has also been accumulated on acyclovir. Early clinical trials suggested large survival benefits in patients with advanced HIV disease after 1 year of JID 1998;178 (August)
Statistical Methods

follow-up whenever possible, beyond the original analysis of the data and with detailed individual patient information on
Pooled analysis. The mortality data of each trial separately important covariates that may predict mortality in HIV-infected and of all trials together stratified according to study were analyzed patients. This offered an opportunity to synthesize all of the with Kaplan-Meier plots, with comparisons made with the logavailable evidence and to assess the extent and reasons of rank test [11] .
potential heterogeneity in the study results.
Fixed-and random-effects meta-analysis. Odds ratios (ORs) and confidence intervals (CIs) were estimated for different time intervals on the basis of deaths occurring within each Methods time interval among the randomized patients still at risk at the beginning of the interval. Heterogeneity between trials was asIdentification and Selection of Studies sessed with a x 2 statistic. Since the statistic can be fairly insensiThe protocol considered all randomized efficacy trials that comtive, heterogeneity was considered significant for P õ .10. The pared high-dose oral acyclovir (at least 3200 mg per day) against ORs were then combined by two different methods: the Mantelno therapy or placebo in patients with HIV infection addressing
Haenszel [12] fixed-effects model, which considers only heteroclinical outcomes including survival. Trials were identified through geneity within studies and assumes that differences between the a Medline search, complemented by searching of abstracts from various studies are only due to chance, and the DerSimonian major meetings, trial directories, and communications with experts, and Laird model [13] , which considers heterogeneity both investigators of the identified trials, and industry researchers. More within and among studies to calculate the range of possible true than 100 people were contacted, and retrieval of the databases treatment effects across studies. Unless stated otherwise, we required coordinated efforts at several data archives in the United report only random-effects estimates. The random-effects model States and Europe over a period of almost 2 years.
is more conservative and tends to provide wider CIs. In the presence of significant heterogeneity, the fixed-effects model would not be as appropriate as the random-effects model, while Data Collected in the absence of among-study heterogeneity, the results of the two models are identical [14] . Separate analyses were done for Investigators and sponsoring agencies were asked to provide the survival at 6, 12, 24, 36, and 48 months and for the complete following data on all randomized subjects: patient identification follow-up. The OR has been traditionally used in the analysis number, treatment assignment, date of randomization (start), latest of clinical trials. However, it may overestimate the magnitude date known to be alive and survival status, and baseline characterisof the treatment effect when it is interpreted as a risk ratio. tics including-at the minimum-age, sex, race, baseline CD4
Therefore, for the analysis of the complete follow-up, we also cell count, hemoglobin level, and previously recorded diagnosis obtained the more conservative pooled incidence risk ratios of AIDS. These data were consistently collected and recorded for (representing the ratio of events per patient-years of follow-up all trials. Investigators were asked to provide all follow-up data, in the acyclovir arm divided by events per patient-years of folincluding follow-up beyond what had been reported in original low-up in the control arm) [15] . publications or in original executive summaries of unpublished Subgroup analyses. Subgroup analyses were done along the studies. Additional data collected across trials included causes of same principles as the main analyses, focusing on data from the death and occurrence of disease attributable to cytomegalovirus whole duration of follow-up and using only the patients belonging (CMV), herpes simplex virus (HSV), or varicella-zoster virus to each specific subgroup from each trial. Subgroups were consid-(VZV) infections, but for these data information was typically ered for age at entry (õ30, §30), sex, race (white vs. other), limited to the original trial follow-up, with no information on the baseline CD4 cell count (ú100 and £100/mm 3 ), baseline hemoextension periods. The few identified data inconsistencies were globin level (õ11 and §11 g/dL), and reported diagnosis of AIDS clarified with communications between the meta-analysis team and at entry. The cutoff values for the main subgroup analyses were the local data managers and investigators.
pre-specified before analyses were undertaken. Heterogeneity within and among subgroups was assessed by the x 2 test. Proportional hazards modeling. A separate approach used a End Points proportional hazards model for the time to death [16] . Hazard ratios were estimated for acyclovir treatment versus placebo or no The major end point addressed in the meta-analysis was survival, based on individual patient data. Secondary end points addressed treatment, both unadjusted and adjusted for study and for age, sex, race, baseline CD4 cell count (used as the square root of the value), included recorded morbidity that is related to acyclovir-susceptible herpesviridae, including HSV and VZV infections; occurrence of baseline hemoglobin level, and diagnosis of AIDS at entry in multivariate models. A multivariate model including only variables new CMV end-organ disease; and death from lymphoma and from Kaposi's sarcoma because of their potential associations with herselected from forward selection according to a log likelihood ratio with P õ .05 for entry and P ú .10 for removal of variables gave pesviruses (Epstein-Barr virus and human herpesvirus 8, respectively). Incidence data on new diagnoses of lymphoma and similar results for the significant predictors (not reported). For missing predictor values, we performed one analysis excluding Kaposi's sarcoma were not consistently available. Secondary end points were analyzed based on group data from each trial. All these patients and a separate analysis imputing median study values. The results were practically identical, and only the latter are analyses followed the intention-to-treat principle and no patients were excluded.
reported.
Results
of death on the basis of baseline CD4 cell count, baseline hemoglobin level, age, and prior recorded AIDS diagnosis. The efficacy
Characteristics of individual trials. We obtained informaof acyclovir was evaluated separately in the four quartiles of pation on the existence of 11 randomized controlled trials [6-9, tients with low, moderate, high, and very high risk.
19-24] of acyclovir in HIV-infected patients. We found no
Secondary end points. For secondary end points, data were trials comparing low-dose oral acyclovir against placebo or no more limited to allow analyses at different time points. ORs for treatment. One small study of 30 patients [19] was excluded events recorded during the whole conduct of each trial were pooled from the meta-analysis because it used intravenous acyclovir according to the same principles of fixed-and random-effects mod-(50 mg/kg) only once weekly and in this trial, over its shortels as for the primary end point, and heterogeneity was similarly term follow-up (4 months), no deaths were recorded. Two more assessed. Since there were several secondary end points, we agreed small trials of 12 and 21 patients, respectively [23, 24] , were a priori to use a more strict level of statistical significance (a Å not included, as their focus was on pathogenesis, no deaths
.01) to account for multiple comparisons.
occurred among their participants, and secondary end points Patients with ARC in H56-002 ARC were eligible if they had weight loss of ú10% or ú7 kg and/or oral candidiasis and at least 1 of following: diarrhea of unknown cause, fever of unknown cause ú38ЊC for ú3 weeks, oral hairy leukoplakia, herpes zoster, or persistent lymphadenopathy involving §2 extrainguinal sites.
† No. of HSV/VZV episodes during main study pertains to acyclovir and control arms combined. Given large efficacy of acyclovir to suppress clinical HSV and VZV infections, large majority of events occurred in control arm; therefore, rates of HSV/VZV are largely reflective of risk of clinical herpesvirus infections in each study population and not so much of length of ACV exposure.
‡ ACTG 010 had total of 67 patients, but data were retrievable only from 41 patients of main unit. No deaths had been recorded in main study follow-up in other 26 patients. Also, ACTG 010 was only open-label study in meta-analysis. All other trials were double-blind, placebo-controlled.
§ Does not include HSV or VZV recurrences that were not systematically recorded in ACTG 063; in other trials, recurrences accounted for Ç25% of count of episodes.
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06-03-98 21:47:54 jinfa UC: J Infect of H14-326, which was launched in 1992. The use of Pneumothe onset [6, 22] , most studies used zidovudine as original background therapy. With the exception of 2 small studies cystis carinii pneumonia prophylaxis was not systematically recorded but was uncommon in the main follow-up of studies [20, 21] that did not systematically collect long-term followup information, the median follow-up was ú1 year in all studlaunched before 1988 (H56 studies and ACTG 010), while it became standard in studies launched in 1989 or later, in particuies, and the maximal follow-up was 3.4 -5.1 years. The 2 small studies with suboptimal follow-up information had inconclular ACTG 063 and H14-325, whose patients would qualify for P. carinii prophylaxis (P53 and H14-326 targeted patients with sive results, with soft trends in opposite directions. The total follow-up of all studies amounted to 2947 person-years. The early disease).
The median CD4 cell count in the included studies varied median duration of acyclovir treatment on study varied from 0.4 to 1.8 years. Overall, 523 deaths (29% of randomized pafrom 34 to 607/mm 3 . With the exception of 2 studies that left antiretroviral therapy at the discretion of the investigator from tients) were recorded, including 247 of 895 patients allocated Primary end point. Figure 1 shows the analysis for survival for patients with ú150 CD4 cells/mm 3 . Any observed soft trends should be interpreted with great caution for this analysis. for each of the trials separately and a survival analysis including the data from all trials. There was evidence for superiority of
In a proportional hazards model (table 4) , the hazard of death was significantly decreased with acyclovir (P Å .006). Higher acyclovir over no treatment (P Å .046, unstratified log-rank test; P Å .006, log-rank test stratified for study). Acyclovir baseline CD4 cell count, higher baseline hemoglobin level, and younger age were also significantly associated with reduced gained superiority over no treatment within the first 6 months. There was a suggestion that the two survival curves approached hazard of mortality (P õ .001 for all adjusting covariates). The results were similar when multivariate models were used and each other during the second year. This may reflect crossover to acyclovir from the control arm, which occurred usually at were not affected by the model-building approach, and the effect of acyclovir was still significant (P Å .005). the end of 1 year in most trials, or it could be only chance fluctuation. The extent of acyclovir use beyond the original The results were similar when patients were stratified in quartiles according to their estimated risk of death on the basis main follow-up has not been recorded in these trials. Table 2 shows the pooled OR for different time intervals. There was of their baseline CD4 cell count and hemoglobin level, age, and history or not of AIDS at entry (table 5) . There was no no significant heterogeneity between the results of different studies, both for the whole follow-up and within specific time heterogeneity of the OR in different quartiles. However, in the low-risk quartile, the risk of mortality was very small (0.9% intervals. The pooled results suggested a marginally significant reduction in the odds of mortality in the acyclovir-allocated over a median follow-up of almost 2 years), so the absolute magnitude of any survival benefit would be negligible. patients (OR, 0.75; 95% CI, 0.57 -1.00 [ figure 2A ]; incidence risk ratio, 0.81; 95% CI, 0.68 -0.96 [ figure 2B ]; no heterogeneSecondary end points. Acyclovir significantly decreased the number of patients who had clinically evident HSV infecity between studies).
The results of pre-specified subgroup analyses are shown in tions (70 vs. 205; OR, 0.28; 95% CI, 0.21 -0.37; P õ .001) and VZV infections (14 vs. 54; OR, 0.29; 95% CI, 0.13 -table 3. For all of the considered covariates of interest, there was no evidence of significant heterogeneity in the treatment 0.63; P Å .002) ( figure 3 ). There was no significant difference between the acyclovir and control arms in the occurrence of benefit from acyclovir in different patient categories. The benefit of acyclovir was fairly similar in patients with £100 or CMV disease (40 vs. 39; OR, 1.02; 95% CI, 0.64 -1.63) and in deaths primarily due to Kaposi's sarcoma (11 vs. 18; OR, ú100 CD4 cells/mm 3 , in patients with or without anemia, and in patients with or without AIDS at entry. The treatment effect 0.62; 95% CI, 0.29 -1.36) or due to lymphoma (10 vs. 12; OR, 0.83; 95% CI, 0.35 -1.92). There was no significant heterogewas similarly not significantly affected by age, sex, and race. An exploratory a posteriori analysis looking at smaller CD4 neity between studies for any of the secondary end points (P ú .2 for all). cell count subgroups also did not reveal statistically significant differences among CD4 cell count subgroups (P ú .3 for heter-
The incidence of clinical HSV and VZV infections varied substantially among the different trials. Three studies recorded ogeneity between CD4 cell count subgroups). The random ef-£18 episodes/100 patient-years of follow-up, while the other 4 studies in which data were available recorded anywhere from 25 to 62 episodes/100 patient-years of follow-up (table 1) . infections in the different trial populations. Acyclovir had no tions that showed a survival benefit from acyclovir. All of the trials we analyzed used high doses of acyclovir and were effect on mortality from Kaposi's sarcoma or lymphoma and did not affect the incidence of CMV disease. There was no designed with the hypothesis that prevention of herpesviruses affected by high doses of acyclovir would enhance outcome. significant evidence that the benefit from acyclovir varied among different age groups, in patients with different CD4 cell
The observation that patients with higher CD4 cell counts seemed to experience the same benefit suggests that herpesvicounts and hemoglobin levels, or in those with or without a prior diagnosis of AIDS, although all of these covariates were ruses that reactivate frequently, even at CD4 cell counts ú100, may be a factor in acyclovir effects. Given the known susceptiassociated with the risk of death. Any survival benefits would be clinically negligible for patients at low risk of death.
bility profiles of herpesviruses, the effect could have been mediated through an effect on HSV and VZV, although a mechaThe mechanism by which acyclovir might have prolonged survival is unknown, but the reduction in the incidence of HSV nism involving human herpesvirus 6 [3] or Epstein-Barr virus or a still-unknown susceptible herpesvirus as well cannot be and VZV infections in all studies suggests that suppression of the bursts of HIV replication occurring during active herpesvicompletely excluded. Recent investigations have shown that the frequency of HSV reactivation in HIV-infected patients is rus infections is one potential explanation [1, 2, 26, 27]. Differences across different trials could have been due to chance
substantially larger than what is suggested by the number of clinically identifiable recurrences [28] . If the beneficial effect alone, but it is intriguing that it was only trials with a very high incidence of clinically identifiable HSV and VZV infecis mediated through HSV and VZV, then lower doses of presented [39] , and a direct synergistic anti-HIV effect is controversial.
* According to DerSimonian and Laird model [13] ; there was no heterogene-
The long controversy of herpes prophylaxis in HIV infection ity among trials within any analyzed subgroup; thus, fixed-effects estimates were very similar (not reported). Also, there was no significant heterogeneity highlights the difficulty of drawing conclusions from observabetween subgroups for any of considered predictors. There were missing basetional studies or even a single large randomized trial. Great line CD4 cell counts, baseline hemoglobin measurements, age, sex, and race data for 31 (1.7%), 74 (4.1%), 3 (0.2%), 2 (0.1%), and 2 (0.1%) patients, respectively; 46 of 74 baseline missing hemoglobin data were from ACTG 010, in which hemoglobin files could not be retrieved, but it is known that no patients had anemia (thus, imputed median value is likely to be largely accu- these studies suggesting that acyclovir also had no effect on showed that acyclovir did not affect mortality related to lymphoma, although the power to show an effect was very time-independent proportionality was not rejected (P Å .25 and P Å .11, others) could not be differentiated in the available trial datarespectively, for 2 approaches). CI, confidence interval.
bases. An observational study [33] has suggested a reduced * Multivariate model considered all listed variables (also stratifying for study). Multivariate model including only variables selected from forward incidence of non-Hodgkin's lymphoma (where Epstein-Barr selection according to log likelihood ratio with P õ .05 for entry and P ú .10 virus has been implicated) in association with high-dose for removal of variables gave similar results for significant predictors. When acyclovir use. no adjustment for study was made, results were similar, with exception of prior AIDS diagnosis becoming fully significant (most studies either allowed
The acyclovir studies included in the meta-analysis were no patients with AIDS to enroll or only enrolled patients with AIDS, resulting launched before virus load measurements become available, in confounding of study by AIDS diagnosis); also, nonwhite race became and no data on HIV RNA (arguably the most relevant prognossignificant predictor of increased survival, because nonwhite patients were enrolled mostly in 2 studies with relatively earlier disease.
tic indicator in HIV disease [34, 35] Overall, our results suggest that antiherpetic therapies may possibly have a role in HIV therapeutics, especially in highmortality risks [40] . Observational studies are even less likely to avoid bias, even if meticulous state-of-the-art attempts are risk HIV-infected patients with frequent herpesvirus infections. Prospective studies have indicated that the frequency of HSV made to account for various sources of confounding [41] . This is easily exemplified in the case of observational studies of reactivation among HIV-infected patients has been underestimated and that most of these reactivations are subclinical [28] . acyclovir done by experienced epidemiologists: 1 study [4] suggested a remarkable, but probably exaggerated, 44% reducThis raises the issue that the effect of antivirals on reducing herpesvirus reactivation in currently treated cohorts is of importion in mortality for patients starting acyclovir after the diagnosis of AIDS, while 2 others estimated equally improbable 28% tance and should also be studied. More important than any clinical practice implications, the meta-analysis provides addi- [5] and 48% [42] increases in the odds of death. The observed harm may reflect confounding of the decision to use acyclovir tional data to support the importance of the postulated interactions between herpesviruses and HIV-1 [1, 2, 47, 48] . Other with perceived disease deterioration, intermittent use of acyclovir, use in conjunction with a herpes management indicaagents with broad antiherpetic activity, and preferably anti-CMV activity, acceptable tolerability, and convenient dosing, tion, or other unknown confounders. Meta-analyses, and particularly meta-analyses of randomized individual patient data, are may warrant development and clinical testing in HIV infection. The role of currently available antiherpetic agents, such as difficult and time-consuming to conduct [10] , but, if appropriately done, they have advantages [43, 44] 
